# CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
Canonical URL: https://biopharmsignal.com/news/CRVO/cervomed-to-participate-in-the-4th-annual-roth-healthcare-opportunities-conferen-1d7789e3
Ticker: CRVO
Company: CervoMed
Source: CervoMed
Published: 2025-10-02 12:00 EST
## Summary

CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related...

## Article Body
CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 4 th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Thursday, October 9, 2025.

Panel Details Title: “Small Firms Tackling Blockbuster Indications” Date: Thursday, October 9, 2025 Time: 8:00 AM ET

To request a meeting or for more details about the Conference, please reach out to your institutional representative at Roth.

About CervoMed CervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. The Company’s recently completed Phase 2b trial evaluated neflamapimod in patients with DLB.

Investor Contact: PJ Kelleher LifeSci Advisors Investors@cervomed.com 617-430-7579
## Recent Company News
- 2026-04-22 11:30 EST — [CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies](https://biopharmsignal.com/news/CRVO/cervomed-announces-new-data-at-the-2026-aan-annual-meeting-that-demonstrated-nef-cd73de51) — Source: CervoMed
- 2026-04-07 11:30 EST — [CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting](https://biopharmsignal.com/news/CRVO/cervomed-to-provide-neflamapimod-clinical-program-update-and-participate-in-a-pa-a8806faf) — Source: CervoMed
- 2026-03-19 11:30 EST — [CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology](https://biopharmsignal.com/news/CRVO/cervomed-announces-new-data-at-the-ad-pd-2026-scientific-conference-that-reinfor-c5e9beb0) — Source: CervoMed
- 2026-03-17 11:30 EST — [CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates](https://biopharmsignal.com/news/CRVO/cervomed-reports-fourth-quarter-and-full-year-2025-financial-results-and-provide-bb15de98) — Source: CervoMed
- 2026-03-12 11:00 EST — [CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference](https://biopharmsignal.com/news/CRVO/cervomed-announces-presentations-at-upcoming-ad-pd-2026-scientific-conference-fb00b88c) — Source: CervoMed
## Related News
- 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a)
- 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce)
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)